The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Authors: Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial

Source: Blood Cancer Journal, Vol 15, Iss 1, Pp 1-11 (2025)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2044-5385

Access URL: https://doaj.org/article/e9acc5143e2743b68c74d2d9721a4b12

Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment

Authors: Caitlin Thomas, Sikander Ailawadhi, Rakesh Popat, David Kleinman, Melissa M. Ross, Boris Gorsh, Sarah Mulnick, Alicia O’Neill, Prani Paka, Maya Hanna, Nicolas Krucien, Alexa Molinari, Heather L. Gelhorn, Sue Perera

Source: Frontiers in Medicine, Vol 10 (2023)

Subject Terms: benefit–risk, discrete choice experiment, multiple myeloma, patient preferences, trade-offs, treatment attributes, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fmed.2023.1271657/full; https://doaj.org/toc/2296-858X

Access URL: https://doaj.org/article/fb95510a02b3487884e1677723bf17e9

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study

Authors: Alexis Talbot, Arthur Bobin, Léa Tabone, Jérôme Lambert, Catherine Boccaccio, Cécile Deal, Marie-Odile Petillon, Olivier Allangba, Philippe Agape, Pierre Arnautou, Rakiba Belkhir, Sylvie Cailleres, Driss Chaoui, Marie-Lorraine Chrétien, Olivier Decaux, Samantha Schulmann, Laurent Frenzel, Lauris Gastaud, Antoine Huart, Cyrille Hulin, Lionel Karlin, Kamel Laribi, Ronan Le Calloch, Pascal Lenain, Margaret Macro, Salomon Manier, Lydia Montes, Stéphane Moreau, Philippe Moreau, Véronique Morel, James Norwood, Frédérique Orsini Piocelle, Aurore Perrot, Gian Matteo Pica, Philippe Rey, Anna Schmitt, Anne-Marie Stoppa, Mourad Tiab, Cyrille Touzeau, Valérie Vidal, Marguerite Vignon, Laure Vincent, Zoé Van De Wyngaert, Charles Zarnitsky, Naima Kerbouche, Prani Paka, Xavier Leleu, Bertrand Arnulf, Hervé Avet-Loiseau, IFM: Intergroupe Francophone du Myélome

Source: Haematologica, Vol 108, Iss 10 (2023)

Subject Terms: Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://haematologica.org/article/view/11056; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

Access URL: https://doaj.org/article/b1c5d27182c748cbbd625be53da24488

This result is not displayed to guests.
Login for full access.

P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.

Authors: Lonial, Sagar, Nooka, Ajay, Thulasi, Praneetha, Badros, Ashraf Z., Jeng, Bennie, Callander, Natalie S., Sborov, Douglas, Zaugg, Brian E., Popat, Rakesh, Esposti, Simona Degli, Baron, January, Doherty, Allison, Lewis, Eric, Opalinska, Joanna, Prani Paka, Piontek, Trisha, Gupta, Ira, Farooq, Asim V., Jakubowiak, Andrzej

Source: Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 2, Vol. 21, pS149-S150, 2p